Australian biotech market watch 17/11/09
Tuesday, 17 November, 2009
The All Ordinaries has retracted after seeing a surge in early trading. As of 2.45pm this afternoon it's down 18 points to 4,755 from a of 4,809 at 10am.
Xenotransplantation specialists, Living Cell Technologies (ASX:LCT), are up by 9.5% to 29c after its announcement of a share purchase plan yesterday. This means the price of 25c per share being offered by LCT is equivalent to a 15% discount from the current price.
Prima Biomed (ASX:PRR) issued a trading halt this morning pending an announcement of an oral vaccine for cervical cancer. It last traded at 16.5c, up 3.1%.
Mesoblast (ASX:MSB) also saw impressive gains this morning, up 8c to $1.36. Cancer drug company, ChemGenex, put on 3.7% to 98.5c.
Also experiencing rises were Sirtex (ASX:SRX), up 16c to $6.66, Ramsay Health Care (ASX:RHC), up 12c to $10.91 and Cellestis (ASX:CST), up 4c to $3.84.
Falls were seen by Blackmores (ASX:BKL), down 1.4% to $20.71, and Ansell (ASX:ANN), down a similar amount to $10.26.
The majors remained fairly steady.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
